Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

NCT06345183 · clinicaltrials.gov ↗

COMPLETED

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma (aRCC)

Interventions

COMBINATION_PRODUCT: Nivolumab + Ipilimumab combination therapy
COMBINATION_PRODUCT: Pembrolizumab + Lenvatinib combination therapy

Sponsor

Bristol-Myers Squibb